Holen Sie sich die Stockscreener-App
1.24
5.34%
-0.07
Handel nachbörslich:
1.23
-0.01
-0.81%
Schlusskurs vom Vortag:
$1.31
Offen:
$1.34
24-Stunden-Volumen:
373.89K
Relative Volume:
0.72
Marktkapitalisierung:
$57.90M
Einnahmen:
$14.51M
Nettoeinkommen (Verlust:
$-21.97M
KGV:
-2.0992
EPS:
-0.5907
Netto-Cashflow:
$-7.22M
1W Leistung:
+11.71%
1M Leistung:
-10.79%
6M Leistung:
-43.89%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.21
$1.40
1-Wochen-Bereich:
$1.015
$1.49
52-Wochen-Spanne:
$1.015
$2.99
Mindwalk Holdings Corp Stock (HYFT) Company Profile
Firmenname
Mindwalk Holdings Corp
Sektor
Branche
Telefon
-
Adresse
-
Compare HYFT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HYFT
Mindwalk Holdings Corp
|
1.24 | 61.17M | 14.51M | -21.97M | -7.22M | -0.5907 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mindwalk Holdings Corp Stock (HYFT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-25 | Eingeleitet | The Benchmark Company | Buy |
Mindwalk Holdings Corp Aktie (HYFT) Neueste Nachrichten
H.C. Wainwright reiterates Buy on MindWalk stock on SaaS deal - Investing.com
MindWalk Holdings Corp (HYFT) Q3 2026 Earnings Call Highlights: Revenue Surge and Strategic Shifts - GuruFocus
MindWalk Holdings Corp. Q3 2026 Earnings Call Summary - Yahoo Finance
MindWalk Holdings Corp. (HYFT) Posts Third Quarter Loss, Falls Short of Revenue Expectations - Bitget
MindWalk (HYFT) Q3 2026 Earnings Call Transcript - The Globe and Mail
MindWalk Holdings Corp. (HYFT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
MindWalk Holdings Delivers Q3 Revenue Surge and Secures First LensAI Platform Contract - TipRanks
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results - The Joplin Globe
MindWalk launches nanobody discovery platform for bispecifics - Investing.com Nigeria
MindWalk Holdings Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
MindWalk launches nanobody discovery platform for bispecifics By Investing.com - Investing.com Canada
MindWalk Announces B Cell Llama(TM), a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era - irw-press.com
HYFT Stock Price and Chart — NASDAQ:HYFT - TradingView
MindWalk (HYFT) Introduces B Cell Llama for Enhanced Antibody Di - GuruFocus
MindWalk Unveils B Cell Llama Nanobody Platform Backed by Peer-Reviewed Study - TipRanks
New MindWalk (NASDAQ: HYFT) B Cell Llama platform targets bispecific and cell therapies - Stock Titan
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era - Yahoo Finance Singapore
HYFT Forecast, Price Target & Analyst Ratings | MINDWALK HOLDINGS CORP (NASDAQ:HYFT) - ChartMill
HYFT SEC FilingsMindWalk Holdings Corp 10-K, 10-Q, 8-K Forms - Stock Titan
MindWalk Holdings to Report Q3 2026 Earnings - National Today
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026 - 01net
MindWalk Sets March 12 Date to Report Q3 2026 Results and Host Earnings Webcast - TipRanks
MindWalk (NASDAQ: IPA) sets March 12 call on Q3 FY 2026 results - Stock Titan
Bio-Native AI therapeutics MindWalk sets March 12 Q3 earnings call - Stock Titan
HYFT Technical Analysis & ETF Price Forecast - Intellectia AI
Zacks Research Upgrades MindWalk (NASDAQ:HYFT) to Hold - MarketBeat
Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
MindWalk Uses HYFT AI Platform to Expose Hidden Portfolio and IP Risks in Drug Discovery - TipRanks
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Yahoo Finance
MindWalk Launches HYFT Technology to Address Drug Development Risks - intellectia.ai
HYFT Forecast — Price Prediction for 2026. Should I Buy HYFT? - Intellectia AI
After Leaping 47% MindWalk Holdings Corp. (NASDAQ:HYFT) Shares Are Not Flying Under The Radar - 富途牛牛
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease - BioSpace
Mindwalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic Tdp-43 in Neurodegenerative Disease - marketscreener.com
Scientists trace a hidden flu constraint across strains and hosts - Stock Titan
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight - Yahoo Finance
MindWalk (HYFT) Makes Progress in Influenza Research with Key Di - GuruFocus
MindWalk Holdings Corp. Advances Universal Influenza Program with A Breakthrough Functional Insight - marketscreener.com
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight - 01net
MindWalk Unveils Cross-Strain Functional Constraint to Advance Universal Flu Vaccine Effort - TipRanks
MindWalk : Charter of the Audit Committee of the Board of Directors - marketscreener.com
MindWalk Holdings Corp.'s (NASDAQ:HYFT) P/S Is Still On The Mark Following 38% Share Price Bounce - Sahm
MindWalk Holdings Corp. (HYFT) Competitors - Meyka
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
HYFT: MindWalk Holdings Corp.Balance Sheet - Zacks Investment Research
MindWalk Holdings Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HYFT) 2025-12-18 - Seeking Alpha
MindWalk Holdings Corp. (HYFT) reports Q2 loss, lags revenue estimates - MSN
MindWalk : Second Quarter 2026 Transcript - marketscreener.com
MindWalk reports 54% revenue growth in Q2 fiscal 2026 By Investing.com - Investing.com Australia
Finanzdaten der Mindwalk Holdings Corp-Aktie (HYFT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):